Yaxin Li

Dr. Yaxin Li

orcid

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 November 2003 in Nature Biotechnology
Verified
Journal Article
Closed access
JZJian-Zhou Zhao
Jian-Zhou Zhao
JCJun Cao
Jun Cao
YLYaxin Li
Yaxin Li
HCHilda L Collins
Hilda L Collins
RRRichard T Roush
Richard T Roush
ASAnthony Shelton
Anthony Shelton

22 March 2024 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
LYLeifu Yang
Leifu Yang
YLYaxin Li
Yaxin Li
YDYunling Du
Yunling Du
YGYan Guo
Yan Guo
ZGZhenke Guo
Zhenke Guo
LHLiming Hu
Liming Hu

23 October 2023 in Journal of Biomolecular Structure and Dynamics
Verified
Journal Article
Closed access
YLYaxin Li
Yaxin Li
SLSisi Liu
Sisi Liu
XXXiming Xu
Ximing Xu
JXJiamin Xu
Jiamin Xu
LYLeifu Yang
Leifu Yang
LHLiming Hu
Liming Hu
The high structural homology of histone deacetylases 6 and 8 (HDAC6/8) poses a challenge in achieving isoform selectivity and has resulted in adverse side effects due to pan-inhibition in clinical applications. Additionally, the rational design of dual-target inhibitors, centered on HDAC6/8, demands a profound understanding of their selectivity mechanisms. Addressing the urgent need for enhanced specificity in the development of inhibitors targeting specific isoforms, we elucidate the mechanism underpinning the selective inhibition of HDAC6/8 inhibitors through in-silico strategies. The hydrogen bonding interaction with Asp101 and Tyr306 is a key factor that enables compound 12b to selectively inhibit HDAC8. Its favorable spatial orientation places the Cap group of 12b between Tyr306 and Tyr100, resulting in an overall L-shaped conformation. These two factors significantly contribute to the selective inhibitory activity of 12b against HDAC8. The zinc binding group (ZBG) of compound NN-390 forms a hydrogen bond with His610, a key residue of HDAC6, facilitating stable chelation with zinc ions. In addition, the Cap group of NN-390 interacts with Phe620 and Phe680 via van der Waals forces, leading to an overall Y-shaped conformation. The aforementioned factors are the main reasons for the selective inhibition of HDAC6 by NN-390. Furthermore, whether the Cap group is in the para or meta-position will influence the selective inhibition of either HDAC6 or HDAC8. We believe these clues can offer valuable insights for the rational design of selective inhibitors targeting HDAC6/8 and pave the way for rational design of dual-target HDAC6/8-based inhibitors.Communicated by Ramaswamy H. Sarma.

2 September 2024 in Physical Chemistry Chemical Physics
Verified
Journal Article
Closed access
PDF file
YLYaxin Li
Yaxin Li
SLSisi Liu
Sisi Liu
ZWZhuoya Wang
Zhuoya Wang
XWXiaoli Wang
Xiaoli Wang
JXJiamin Xu
Jiamin Xu
LHLiming Hu
Liming Hu
Transforming growth factor β type 1 receptor (TGFβR1), a crucial serine-threonine kinase, is central to the TGFβ/Smad signaling pathway, governing cellular processes like growth, differentiation, apoptosis, and immune response. This pathway is closely linked to the epithelial–mesenchymal transition (EMT) process, which plays an important role in the metastasis of hepatocellular carcinoma (HCC). To date, only limited inhibitors targeting TGFβR1 have entered clinical trials, yet they encounter challenges, notably high toxicity, in clinical applications. Herein, an efficient virtual screening pipeline was developed. Eighty compounds were screened from a pool of over 17 million molecules based on docking scores and binding free energy. Four compounds were manually selected with the assistance of enhanced sampling method BPMD (binding pose metadynamics). The binding stability of these four compounds complexed with TGFβR1 was subsequently studied through long-timescale conventional molecular dynamics simulations. The three most promising compounds were subjected to in vitro bioactivity assays. Cpd272 demonstrated moderate inhibitory activity against TGFβR1, with an IC50 value of 1.57 ± 0.33 μM. Moreover, it exhibited cytotoxic effects on human hepatocellular carcinoma cell line Bel-7402. By shedding light on the binding mode of the receptor–ligand complexes, Cpd272 was identified as a hit compound featuring a novel urea-based scaffold capable of effectively inhibiting TGFβR1.

1 July 2022 in Letters in Drug Design & Discovery
Verified
Journal Article
Closed access
PDF file
SLSisi Liu
Sisi Liu
YLYaxin Li
Yaxin Li
JWJin Wang
Jin Wang
XRXue Rui
Xue Rui
HTHaobo Tian
Haobo Tian
CGChunyan Guo
Chunyan Guo
Background: Protein kinase B (Akt) is a serine/threonine-protein kinase that drives the diverse physiological process. Akt is a promising therapeutic target, which involves cancer cell growth, survival, proliferation and metabolism. Objective: The study aims to design highly active Akt inhibitors, and to elucidate the structural requirements for their biological activity, we analyzed the key binding features and summarized the structural determinants for their bioactivities. Methods: A series of piperidine derivatives have been investigated employing three-dimensional quantitative structure-activity relationship (3D-QSAR), molecular docking and molecular dynamics simulation. Results: The statistics of the comparative molecular field analysis (CoMFA) model (Q2=0.631, R2=0.951) and the comparative molecular similarity index analysis (CoMSIA) model (Q2=0.663, R2=0.966) indicated that our 3D-QSAR model was accurate and reliable. Besides, the stability of receptor-ligand interactions under physiological conditions was then evaluated by molecular dynamics simulation, in agreement with the molecular docking results. Conclusion: Our study provided valuable insights for the discovery of potent Akt inhibitors.

18 February 2026 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
YLYaxin Li
Yaxin Li
SLSisi Liu
Sisi Liu
SHSha Hu
Sha Hu
RZRanran Zhang
Ranran Zhang
XWXiaoli Wang
Xiaoli Wang
LHLiming Hu
Liming Hu